Gordon Findlay Biography – Gordon Findlay Wiki

Gordon Findlay currently holds the position of Global Brand Director at Novo Nordisk, a leading pharmaceutical company with its main headquarters in Bagsværd, Denmark. Since 2023, he has been managing his responsibilities from the company’s base in Basel, Switzerland. In addition to overseeing global brand strategies, Findlay is actively involved in new product planning, strategic marketing, and various global marketing initiatives.

As detailed on his LinkedIn profile, Findlay’s professional journey includes a significant tenure at Novartis, another innovative pharmaceutical giant located in Basel. He served as Director for Global New Product Development from January 2016 until September 2023. Prior to that, he was Director for Global Marketing and Primary Care Franchise from January 2012 to December 2015, and he led Global Strategic Marketing from March 2010 to December 2011.

In his earlier career, Findlay also held the position of Director of Marketing at Novartis UK for a brief period from January to June 2019. Before joining Novartis, he was the Director of Worldwide Commercial Development at Pfizer, where he worked from October 2001 to March 2010.

Academically, Findlay is well-credentialed with a PhD in Biochemistry from the University of Kent. He also earned an MBA from The Open University and a Bachelor of Science degree in Biochemistry and Immunology from the University of Strathclyde.

Gordon Findlay Age

While Gordon Findlay’s exact age remains undisclosed to the public, he recently made headlines for a health-related incident. During an event at the Oval Office, where former President Trump addressed the issue of reducing the cost of weight-loss drugs like Ozempic, Findlay reportedly collapsed, drawing considerable attention to the situation.

Gordon Findlay Collapse

Novo Nordisk executive Gordon Findlay reportedly collapsed in the Oval Office during an event where President Trump made a statement on lowering the price of weight-loss drugs, including Ozempic.

David Ricks, CEO of Eli Lilly, was giving remarks when he looked to his right and said, “Are you okay? Gordon, are you okay?” Dr. Mehmet Oz jumped in as the drug executive fell to his knees and collapsed. The press were then ushered out and asked to leave. Robert F. Kennedy Jr., the U.S. Health and Human Services Secretary, was also in the room when the incident happened.

About 30 minutes later, when the press conference resumed, Trump gave an update on the executive’s health.

“One of the representatives of the companies, of one of these companies, got a little bit lightheaded,” he told the press. “We saw he went down, and he’s fine. They just sent him out, and he’s got doctors here. But he’s fine.”

The man was identified as Gordon Findlay, the global brand director for Novo Nordisk, though the pharmaceutical company later shared a statement with multiple outlets suggesting that Findlay was not present at the event.

“Please be aware that CEO Mike Doustdar and EVP, US Operations, Dave Moore were the only two Novo Nordisk representatives in the Oval Office,” a spokesperson for Novo Nordisk said in a statement.